Novartis stock heads into Boston cell and gene therapy conference
Published on 11/04/2026 at 18:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSBoston event puts pipeline in focus
- Advanced Therapies USA takes place in Boston on November 4 and 5.
- Terrapinn lists Novartis Associate Director Pooja Sabhachandani among the speakers.
- The agenda covers cell and gene therapy development, manufacturing, regulation and market access.
Novartis enters a Boston industry conference with a research representative on the published speaker list. Advanced Therapies USA runs on Wednesday, November 4, and Thursday, November 5, at the Hynes Convention Center.
The event organizer Terrapinn lists Pooja Sabhachandani, Associate Director for Science and Technology at Novartis, among the speakers. Her listing gives Novartis a direct presence in a broader industry program rather than a company-only investor event.
What has changed since our last report
The new detail for investors is the named Novartis speaker in the conference program. The agenda spans cell therapy, gene therapy, viral-vector development, clinical translation, manufacturing, regulation, reimbursement and market access.
Compared with the October 29 report's 143.81 euros, the latest Lang & Schwarz quote was 1.95 percent higher. Novartis stock traded at 146.62 euros on Lang & Schwarz at 18:06 CET on Wednesday, November 4, 2026.
For the current real-time quote of Novartis stock, investors can follow the latest trading activity while the Boston program unfolds.
The SMI provides the relevant Swiss market backdrop for investors.
More news and analyses on Novartis stock will track further company developments and research updates.
Novartis AG at a glance
- Company: Novartis AG
- ISIN: CH0012005267
- WKN: 904278
- Trading symbol: NOT
- Trading venue: Lang & Schwarz
- Quote: 146.62 euros on November 4, 2026, at 18:06 CET
